Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLoans and Notes ReceivablesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBIAT (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBIAT over the past 16 years, most recently at -$1.1 million for Q2 2025.

  • Quarterly results put EBIAT at -$1.1 million for Q2 2025, up 83.81% from a year ago — trailing twelve months through May 2025 was -$38.7 million (down 446.74% YoY), and the annual figure for FY2025 was -$38.7 million, down 422.29%.
  • EBIAT for Q2 2025 was -$1.1 million at Lifecore Biomedical, Inc. \De\, up from -$14.8 million in the prior quarter.
  • Over the last five years, EBIAT for LFCR hit a ceiling of $14.8 million in Q1 2024 and a floor of -$38.5 million in Q4 2021.
  • Median EBIAT over the past 5 years was -$9.3 million (2021), compared with a mean of -$10.6 million.
  • Peak annual rise in EBIAT hit 254.53% in 2023, while the deepest fall reached 919.23% in 2023.
  • Lifecore Biomedical, Inc. \De\'s EBIAT stood at -$38.5 million in 2021, then soared by 76.08% to -$9.2 million in 2022, then skyrocketed by 254.53% to $14.2 million in 2023, then plummeted by 146.22% to -$6.6 million in 2024, then skyrocketed by 82.54% to -$1.1 million in 2025.
  • The last three reported values for EBIAT were -$1.1 million (Q2 2025), -$14.8 million (Q1 2025), and -$6.6 million (Q4 2024) per Business Quant data.